Benzhydrocodone and Acetaminophen · BENZHYDROCODONE HYDROCHLORIDE 4.08 mg/1; ACETAMINOPHEN 325 mg/1 · Tablet · Oral · Zevra Therapeutics, Inc.
NDC 70040-0145-01 · 100 TABLET in 1 BOTTLE, PLASTIC · NDA · View full market →
Only one company currently supplies this market — there is no backup if it stumbles. One of its named manufacturing plants, Kvk-Tech, Inc., failed FDA inspectionwithin the last two years — the agency’s most serious outcome.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Not scored — fragility is computed for NADAC-priced NDCs.
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
There's no legal definition — it meets 1 of 6 public criteria. Why that matters →
| Type | Number / code | Expires |
|---|---|---|
| patent | 8461137 | Feb 22, 2031 |
| patent | 8461137 | Feb 22, 2031 |
| patent | 8461137 | Feb 22, 2031 |
| patent | 9549923 | Jul 1, 2030 |
| patent | 8828978 | Jul 1, 2030 |
| patent | 9549923 | Jul 1, 2030 |
| patent | 8828978 | Jul 1, 2030 |
| patent | 9132125 | Jul 1, 2030 |
| patent | 8828978 | Jul 1, 2030 |
| patent | 9549923 | Jul 1, 2030 |
| patent | 8748413 | Jul 1, 2030 |
| patent | 8748413 | Jul 1, 2030 |
No FDA shortage reports for this drug or its presentations.
No enforcement reports list this package NDC.
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Zevra Therapeutics, Inc. | BENZHYDROCODONE HYDROCHLORIDE 8.16 mg/1; ACETAMINOPHEN 325 mg/1 | Aug 26, 2026 | Sep 2, 2026 |
| Zevra Therapeutics, Inc. | BENZHYDROCODONE HYDROCHLORIDE 4.08 mg/1; ACETAMINOPHEN 325 mg/1 | Aug 26, 2026 | Sep 2, 2026 |
| Zevra Therapeutics, Inc. | BENZHYDROCODONE HYDROCHLORIDE 6.12 mg/1; ACETAMINOPHEN 325 mg/1 | Aug 26, 2026 | Sep 2, 2026 |
| Zevra Therapeutics, Inc. | BENZHYDROCODONE HYDROCHLORIDE 325 mg/1; ACETAMINOPHEN 6.12 mg/1 | Jul 22, 2026 | Aug 19, 2026 |
| Zevra Therapeutics, Inc. | BENZHYDROCODONE HYDROCHLORIDE 325 mg/1; ACETAMINOPHEN 4.08 mg/1 | Jul 22, 2026 | Aug 19, 2026 |
| Zevra Therapeutics, Inc. | BENZHYDROCODONE HYDROCHLORIDE 325 mg/1; ACETAMINOPHEN 8.16 mg/1 | Jul 22, 2026 | Aug 19, 2026 |
| Zevra Therapeutics, Inc. | ACETAMINOPHEN 325 mg/1; BENZHYDROCODONE HYDROCHLORIDE 4.08 mg/1 | Jul 15, 2026 | Jul 15, 2026 |
| Zevra Therapeutics, Inc. | ACETAMINOPHEN 325 mg/1; BENZHYDROCODONE HYDROCHLORIDE 8.16 mg/1 | Jul 15, 2026 | Jul 15, 2026 |
| Zevra Therapeutics, Inc. | ACETAMINOPHEN 325 mg/1; BENZHYDROCODONE HYDROCHLORIDE 6.12 mg/1 | Jul 15, 2026 | Jul 15, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
DrugDashboards, "Apadaz — NDC 70040-0145-01," retrieved September 3, 2026, https://drugdashboards.com/drug/70040014501.
Free to cite with attribution — see how the data is put together.